CriticalDrug for alcohol use disorder, aldehyde dehydrogenase inhibitor×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Disulfiram may slow the metabolism of some drugs, prolong their action and make toxicity more likely. Its SmPC states that it may increase the toxicity of tranylcypromine by inhibiting its metabolism, and isolated cases of delirium have been described with this combination (disulfiram SmPC, AEMPS). Disulfiram and its metabolite diethyldithiocarbamate also inhibit dopamine beta-hydroxylase, which lowers noradrenaline synthesis. As a result, clinically important interactions may occur with drugs that act on the central nervous system through noradrenaline or dopamine (disulfiram SmPC, AEMPS). Full MAO activity returns only 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). The effect of disulfiram may persist for 7–14 days after it is stopped, and up to 20% of a dose may stay in the body for a week or longer (disulfiram SmPC, AEMPS).
Symptoms
According to the Spanish tranylcypromine SmPC, delirium may occur when tranylcypromine is combined with disulfiram (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The disulfiram SmPC describes isolated cases of delirium with this combination and links them to inhibition of tranylcypromine metabolism (disulfiram SmPC, AEMPS). Tranylcypromine poisoning presents with confusion, agitation that can progress to seizures, clouding of consciousness that can deepen into coma, fever and hyperthermia, depressed breathing that can lead to respiratory arrest, severe swings in blood pressure, cardiac conduction disorders and severe muscle spasms. Symptoms may appear several hours later (tranylcypromine SmPC, AEMPS, overdose section). Disulfiram can also cause psychotic episodes or worsen psychotic symptoms on its own (disulfiram SmPC, AEMPS).
Management
The combination is contraindicated: the Spanish tranylcypromine summary of product characteristics (SmPC) names disulfiram among the drugs that must not be given with tranylcypromine (tranylcypromine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The disulfiram SmPC mentions tranylcypromine without a separate prohibition but warns that disulfiram may increase its toxicity (disulfiram SmPC, AEMPS). The strictest document takes precedence. After long-term treatment, withdraw tranylcypromine gradually by lowering the dose, because abrupt withdrawal may cause anxiety, restlessness, sleep disturbance, drowsiness and delirium (tranylcypromine SmPC, AEMPS). After stopping tranylcypromine, the tranylcypromine SmPC recommends waiting 14 days before starting a drug that is incompatible with it, disulfiram included (tranylcypromine SmPC, AEMPS). The documents give no interval between stopping disulfiram and starting tranylcypromine, but the effect of disulfiram may persist for 7–14 days after it is stopped (disulfiram SmPC, AEMPS). The tranylcypromine SmPC lists acute delirium as a contraindication (tranylcypromine SmPC, AEMPS), and the disulfiram SmPC lists psychotic states (disulfiram SmPC, AEMPS). If signs of tranylcypromine poisoning appear, treat the poisoning in intensive care, with monitoring of pulse, blood pressure, breathing and temperature and with mechanical ventilation available. Observe the patient for at least a week, because effects may start late or last a long time (tranylcypromine SmPC, AEMPS, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.3 (2026)– AEMPS, CIMA, nº registro 88524, revisión 08/2026, sección 4.3
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1
- AEMPS: Ficha técnica: Disulfiram, Antabus 250 mg (nº registro 12723), sección 4.5 (2019)– AEMPS, CIMA, nº registro 12723 (Antabus 250 mg comprimidos, Laboratorios Bohm), revisión 01/2019 (texto revisado 05/2014), secciones 4.3, 4.5, 4.8, 5.1 y 5.2